Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
Successful UK market entry programme set to launch for third consecutive year at London Tech Week
West Midlands Growth Company (WMGC) inviting applications from eligible companies for its…
